サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：慢性腎臓病（CKD）治療薬市場 - 成長、将来展望、競合分析、2022年～2030年
市場調査レポート
商品コード
1167480

慢性腎臓病（CKD）治療薬市場 - 成長、将来展望、競合分析、2022年～2030年

Chronic Kidney Disease (CKD) Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 119 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
慢性腎臓病（CKD）治療薬市場 - 成長、将来展望、競合分析、2022年～2030年
出版日: 2022年08月15日
発行: Acute Market Reports
ページ情報: 英文 119 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

慢性腎臓病は非伝染性疾患（NCD）の一つです。全世界で約8億5000万人がCKDと診断されており、2040年までに世界で5番目に多い死亡理由になると推定されています。CKD治療薬市場を牽引する主な要因としては、糖尿病、心血管疾患、CKDの有病率の上昇、高齢者人口の増加などが挙げられます。

当レポートでは、世界の慢性腎臓病（CKD）治療薬市場について調査し、市場の概要とともに、薬剤クラス別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 慢性腎臓病（CKD）治療薬市場：競合分析

  • 主要な慢性腎臓病（CKD）治療薬市場ベンダーの市場ポジショニング
  • 慢性腎臓病（CKD）治療薬市場のベンダーが採用する戦略
  • 主要な業界戦略
  • 階層分析2021年対2030年

第4章 慢性腎臓病（CKD）治療薬市場：マクロ分析と市場力学

  • イントロダクション
  • 世界の慢性腎臓病（CKD）治療薬の市場価値、2020年～2030年、（100万米ドル）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析

第5章 慢性腎臓病（CKD）治療薬市場：薬剤クラス別、2020年～2030年、（100万米ドル）

  • 市場概要
  • 成長と収益分析：2021年対2030年
  • 市場セグメンテーション
    • 高血圧治療薬
    • 高脂血症治療薬
    • 貧血治療薬
    • むくみ治療薬
    • その他

第6章 北米の慢性腎臓病（CKD）治療薬市場、2020年～2030年、（100万米ドル）

第7章 英国およびEUの慢性腎臓病（CKD）治療薬市場、2020年～2030年、（100万米ドル）

第8章 アジア太平洋の慢性腎臓病（CKD）治療薬市場、2020年～2030年、（100万米ドル）

第9章 ラテンアメリカの慢性腎臓病（CKD）治療薬市場、2020年～2030年、（100万米ドル）

第10章 中東・アフリカの慢性腎臓病（CKD）治療薬市場、2020年～2030年、（100万米ドル）

第11章 企業プロファイル

  • AbbVie, Inc.
  • Allergan plc.
  • Amgen Inc.
  • AstraZeneca plc.
  • F. Hoffmann-La Roche Ltd
  • FibroGen
  • GlaxoSmithKline plc.
  • Johnson & Johnson
  • Keryx Biopharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd
  • Pfizer, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
図表

List of Tables

  • TABLE 1 Global Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 2 North America Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 3 U.S. Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 4 Canada Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 5 Rest of North America Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 6 UK and European Union Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 7 UK Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 8 Germany Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 9 Spain Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 10 Italy Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 11 France Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 12 Rest of Europe Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 13 Asia Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 14 China Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 15 Japan Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 16 India Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 17 Australia Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 18 South Korea Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 19 Latin America Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 20 Brazil Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 21 Mexico Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 22 Rest of Latin America Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 23 Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 24 GCC Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 25 Africa Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 26 Rest of Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Chronic Kidney Disease (CKD) Drugs Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Chronic Kidney Disease (CKD) Drugs Market: Quality Assurance
  • FIG. 5 Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class, 2021
  • FIG. 6 Global Chronic Kidney Disease (CKD) Drugs Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Chronic Kidney Disease (CKD) Drugs Market, 2021
  • FIG. 8 Market Positioning of Key Chronic Kidney Disease (CKD) Drugs Market Players, 2021
  • FIG. 9 Global Chronic Kidney Disease (CKD) Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class, 2021 Vs 2030, %
  • FIG. 11 U.S. Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 18 France Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 20 China Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 22 India Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
目次
Product Code: 137463-08-22

Chronic kidney disease (CKD) is also known as chronic kidney failure or renal disease is a condition characterized by a gradual loss of kidney function over time. Key market determinant include rising geriatric populace, increment in prevalence of CKD and favorable insurance policies in developed economies.

The report titled "Chronic Kidney Disease (CKD) Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" provides detailed insights into key market determinants that impacted the market across geographies and drug types. The report also includes market estimation and forecast for CKD drugs for geographic region.

Chronic kidney disease is a non-communicable disease (NCD). About 850 million people across the world are diagnosed with CKD and is estimated to become the fifth most reason of death in the world by 2040. Key factors driving the CKD drugs market include increasing prevalence of diabetes, cardiovascular disease and CKD and increasing geriatric population. More than 10% of the adults were diagnosed by CKD as per Centers for Disease Control and Prevention (CDC). Increasing prevalence of diabetes and hypertension increased the risk of CKD. About 1 in 3 adults were diagnosed for diabetes and 1 in 5 adults with hypertension. Antihypertensive medication contributed to the largest market in the year 2021. ACE inhibitors and diuretics remain as the first line treatment for CKD. Erythropoietin stimulating agents is also used significantly to deal with anemia which is the common complication among CKD affected patients.

North America was the market leader interms of market revenues for CKD drugs market in 2021 in which the U.S. had the highest contribution of market revenues. The key factors that influenced the U.S. CKD market is the increasing in obesity rate, increasing prevalence of diabetic patient. The pipeline molecule such as ABT-614 (Abbott laboratories), EOS789 (Chugai Pharmaceutical) has significant potential. Increasing funding from government agencies and healthcare organizations had a significant role in driving the market for CKD drugs. As per Centers for Disease Control and Prevention, more than 20 million people are diagnosed with CKD every year in the U.S. Europe remained the second largest market in terms of revenues for CKD drugs. High prevalence rate of CKD was the key driver in Europe. However, the highest growth rate was highest in Asia Pacific during the forecast period on 2022 to 2030. The key drivers in Asia Pacific includes rising incidence of diabetes and cardiovascular disorders, emerging healthcare set up and regulations, increased population, increasing development, per capita income and healthcare spending, increasing government initiatives and increase in awareness level among the public.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Chronic Kidney Disease (CKD) Drugs market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Chronic Kidney Disease (CKD) Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

Antihypertensive

Antihyperlipidemic

Anemia Treatment Drugs

Swelling Treatment Drugs

Other

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Chronic Kidney Disease (CKD) Drugs market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Chronic Kidney Disease (CKD) Drugs market?

Which is the largest regional market for Chronic Kidney Disease (CKD) Drugs market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Chronic Kidney Disease (CKD) Drugs market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Chronic Kidney Disease (CKD) Drugs market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Chronic Kidney Disease (CKD) Drugs Market
  • 2.2. Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class, 2021 (US$ Million)
  • 2.3. Global Chronic Kidney Disease (CKD) Drugs Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Chronic Kidney Disease (CKD) Drugs Market: Competitive Analysis

  • 3.1. Market Positioning of Key Chronic Kidney Disease (CKD) Drugs Market Vendors
  • 3.2. Strategies Adopted by Chronic Kidney Disease (CKD) Drugs Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Chronic Kidney Disease (CKD) Drugs Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Chronic Kidney Disease (CKD) Drugs Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Antihypertensive
    • 5.3.2. Antihyperlipidemic
    • 5.3.3. Anemia Treatment Drugs
    • 5.3.4. Swelling Treatment Drugs
    • 5.3.5. Other

6. North America Chronic Kidney Disease (CKD) Drugs Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
  • 6.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)

7. UK and European Union Chronic Kidney Disease (CKD) Drugs Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
  • 7.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)

8. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
  • 8.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)

9. Latin America Chronic Kidney Disease (CKD) Drugs Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
  • 9.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)

10. Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
  • 10.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)

11. Company Profile

  • 11.1. AbbVie, Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Allergan plc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Amgen Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. AstraZeneca plc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. F. Hoffmann-La Roche Ltd
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. FibroGen
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. GlaxoSmithKline plc.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Johnson & Johnson
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Keryx Biopharmaceuticals, Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Kissei Pharmaceutical Co., Ltd
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives
  • 11.11. Pfizer, Inc.
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Portfolio
    • 11.11.4. Strategic Initiatives
  • 11.12. Sanofi S.A.
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Portfolio
    • 11.12.4. Strategic Initiatives
  • 11.13. Teva Pharmaceutical Industries Ltd.
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Portfolio
    • 11.13.4. Strategic Initiatives